Olema Pharmaceutical announced the selection of a 90 mg dose for palazestrant in Phase 3 trials for ER+/HER2- metastatic breast cancer, with updates to be presented at the ASCO Annual Meeting.
Olema Pharmaceutical announced the selection of a 90 mg dose for palazestrant in Phase 3 trials for ER+/HER2- metastatic breast cancer, with updates to be presented at the ASCO Annual Meeting.